Rifaximin: Clinical Use in Adults
Rifaximin is FDA-approved for three specific indications: travelers' diarrhea (TD) caused by noninvasive E. coli in patients ≥12 years, reduction of hepatic encephalopathy (HE) recurrence in adults, and treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults. 1
FDA-Approved Indications and Dosing
1. Travelers' Diarrhea
- Dose: 200 mg three times daily for 3 days 1
- Age: Adults and pediatric patients ≥12 years
- Critical limitation: Do NOT use if diarrhea is complicated by fever or bloody stools, or if caused by pathogens other than E. coli 1
- Action required: If symptoms worsen or persist beyond 24-48 hours, discontinue rifaximin and switch to alternative antibiotics 2
2. Hepatic Encephalopathy (HE) Prevention
- Dose: 550 mg twice daily, ongoing maintenance therapy 1
- Purpose: Reduces risk of overt HE recurrence in adults with advanced liver disease
- Long-term safety: Demonstrated safe for ≥24 months with continued reduction in HE-related hospitalizations (rate 0.21 vs 0.72 with placebo) without increased adverse events or C. difficile infections 3
3. Irritable Bowel Syndrome with Diarrhea (IBS-D)
- Initial treatment dose: 550 mg three times daily for 14 days 2, 1
- Retreatment: Patients experiencing symptom recurrence can be retreated up to 2 times with the same 14-day regimen 2, 1
The 2022 AGA guidelines provide a conditional recommendation for rifaximin in IBS-D, acknowledging moderate-quality evidence but noting that improvements may be small and not always clinically meaningful. 2 The British Society of Gastroenterology (2021) similarly positions rifaximin as a second-line agent, noting its limited effect on abdominal pain specifically 4
IBS-D Treatment Algorithm:
- Best for: Patients with predominant diarrhea, bloating, and stool consistency issues rather than severe abdominal pain 2, 4
- Response assessment: Evaluate after initial 14-day course; responders show ≥30% reduction in abdominal pain AND ≥50% reduction in loose stool frequency for ≥2 weeks during 4-week post-treatment period 2
- Retreatment criteria: If initial response achieved but symptoms recur, repeat the same 14-day course (up to 2 additional times) 2, 5
- Efficacy data: 38.1% response rate with retreatment vs 31.5% with placebo; significant improvements in abdominal pain (50.6% vs 42.2%) and urgency, but not stool consistency alone 5
Contraindications
Absolute contraindication: History of hypersensitivity to rifaximin, any rifamycin antimicrobial agent, or any component of the formulation 1
Safety Considerations and Warnings
Key Safety Points:
- C. difficile risk: Evaluate for C. difficile-associated diarrhea if diarrhea occurs after therapy or worsens during treatment 1
- Hepatic impairment: Use with caution in severe hepatic impairment (Child-Pugh Class C) 1
- Drug interactions: Exercise caution with concomitant P-glycoprotein inhibitors (e.g., cyclosporine) as they may increase rifaximin systemic exposure 1
- Warfarin interaction: Monitor INR and prothrombin time; warfarin dose adjustment may be needed 1
Adverse Event Profile:
- TD: Headache most common (≥2%) 1
- HE: Peripheral edema, nausea, dizziness, fatigue, ascites (≥10%) 1
- IBS-D: ALT elevation, nausea (≥2%) 1
- Overall: Adverse event rates comparable to placebo across all indications 2, 5
Pregnancy Considerations:
May cause fetal harm - this is an important counseling point 1
Administration
Clinical Positioning
For IBS-D specifically, rifaximin ranks as a second-line agent behind 5-HT3 antagonists (which are likely most efficacious) but is particularly useful when:
- Abdominal pain is not the predominant symptom
- Diarrhea, bloating, and urgency are the primary complaints
- Patient has failed first-line therapies
- Long-term safety profile is a priority (no systemic absorption, minimal resistance concerns with intermittent use) 4
The retreatment trial design validates clinical practice: treat for 14 days, observe for response, and retreat only if symptoms recur after initial response 2, 5. This intermittent approach minimizes antibiotic exposure while maintaining efficacy.